Skip to main content

Original Research

Original Research
06/16/2025
John P. Geisler, MD, PharmD, MS; Nagadharshan Devendra, MD; Kelly J. Manahan, MD, MBA
This study evaluates how indication-specific pricing for bevacizumab in cervical and colon cancer could align with a $100 000 per quality adjusted life-year willingness-to-pay threshold.
This study evaluates how indication-specific pricing for bevacizumab in cervical and colon cancer could align with a $100 000 per quality adjusted life-year willingness-to-pay threshold.
This study evaluates how...
06/16/2025
Journal of Clinical Pathways